The American Society of Clinical Oncology (ASCO) congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher and skilled administrator, Dr. Collins appreciates the critical role that federal research plays in advancing our understanding of how to prevent, diagnose, and treat cancer and other life-threatening diseases, and has worked tirelessly to ensure that the United States remains at the forefront of biomedical innovation.
“The American Society of Clinical Oncology (ASCO), the leading professional organization representing over 42,000 physicians and other healthcare providers who care for people with cancer, strongly supports North Carolina House bill 206, which would address inappropriate cost-sharing burdens for oral anti-cancer drugs for the state’s cancer patients.
ALEXANDRIA Va. -- The American Society of Clinical Oncology, Inc. (ASCO®) and Illumina, Inc. today announced a joint contribution of variant interpretations of 6,000 associations of somatic genetic alterations—variants linked to tumors—to the CIViC (Clinical Interpretation of Variants in Cancer) resource, an openly accessible database hosted by Washington University in St. Louis.
CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy ̶ chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects.
CHICAGO – Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13-15 months. All patients relapse despite initial chemotherapy, more than 50% of them within six months after stopping treatment. There are currently no effective therapeutic options for patients with MPM.
CHICAGO – Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ALK inhibitor alectinib (Alecensa) halted cancer growth for a median of 15 months longer and caused fewer severe side effects.
CHICAGO – A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.
CHICAGO – Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted medicines for this disease, second-generation EGFR inhibitor dacomitinib delayed cancer growth by a median of 5.5 months more.
CHICAGO – After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy. In an analysis of six clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months in patients with relatively lower recurrence risk and caused fewer side effects, particularly nerve damage.
CHICAGO – A randomized clinical trial of 766 patients shows that a simple intervention ̶ a web-based tool that enables patients to report their symptoms in real time, triggering alerts to clinicians ̶ can have major benefits, including longer survival. Patients with metastatic cancer who used the tool to regularly report symptoms while receiving chemotherapy lived a median of 5 months longer than those who did not use the tool.
CHICAGO – Findings from a phase III clinical trial of about 300 women may introduce PARP inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced the chance of progression of advanced, BRCA-related breast cancer by 42%, delaying progression by about 3 months.
CHICAGO – A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone, but 83% with standard therapy plus abiraterone. This is the largest study of abiraterone as first-line therapy for advanced prostate cancer.
CHICAGO – Scientists may have developed the first targeted, oral, tumor-type agnostic therapy – a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment resulted in responses in 76% of patients. Response to larotrectinib has been durable, with 79% of responses ongoing 12 months after starting treatment.
CHICAGO – The American Society of Clinical Oncology’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility.
CHICAGO – Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing is not yet routine care.